Key Findings:  Although many studies have explored the in vitro mechanisms and population-based evidence for cannabinoids, there have been no clinical trials to date for urological cancer patients. Currently, there is no conclusive evidence to support patient claims for starting on cannabinoid monotherapy for anticancer benefit when all other avenues for therapy have failed.
Type of Study:  Meta-analysis
Study Result:  Inconclusive
Study Location(s):  Canada
Year of Pub:  2019
Cannabinoids Studied:  2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified)
Receptors Studied:  CB1, CB2